Listing sponsor / Agent
The issuer was founded in 1995 and is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products that are based on proprietary drug delivery technologies of the company and have fewer side effects, increased patient convenience and better efficacy than existing therapies.
Introduction by public issue of new shares
Initial Public offering
Offering of up to 4,9 million newly issued ordinary shares, at a price range of EUR 4,65 to EUR 5,50 per Share.
Date of first listing: 4 October 2006 Settlement: 9 october 2006